Objective: To assess the vaccination history and the status of vaccine-induced protection from measles and rubella in children after treatment for acute lymphoblastic leukemia.
Introduction
Specific immunoresponse abnormalities, both cellular and humoral, have been detected in around 80% of children after conventional treatment for malignant neoplasms, including acute lymphoblastic leukemia (ALL). 1 The underlying disease and the treatment itself both result in significant immunosuppression, which can remain even after white blood cell counts have returned to normal. 2 Assessment of the immune status of these patients with reference to common childhood diseases, after completion of their treatment, is a subject that, while relevant, has received little study. Such assessment allows the immunological status of these children to be investigated through their serological status for diseases against which they have previously been immunized. It is on this analysis that recommendations on the immunization of these patients will be based, since the ideal revaccination schedule is still the subject of discussion. 3 In this study we assess the impact that treatment for ALL has on vaccine-afforded protection against measles and rubella and we also verify whether or not it is necessary to revaccinate these patients at the end of their treatment. to a high risk program, and 10 patients were treated according to a low risk program. All had completed antileukemia treatment and were in complete remission from the disease.
Methods

Twenty
A 6 mL blood sample was collected from each patient and centrifuged at 3,000 rpm for 15 min, separated into 500 µL aliquots and stored at -20 ºC.
At the end of the collection phase, serology was run for rubella and measles by the ELISA (enzyme-linked immunosorbent assay) method. 4 Serological tests for rubella were run using a commercial kit, Enzygnost ® AntiRubella-Virus/IgG (Dade-Behring).
Efficacy of measles vaccination was assessed by measuring immunoresponse by means of seroconversion titers or from the geometric mean of post-vaccination sample titers. 5 
Results
The 22 children suffering from ALL were assessed. Age at assessment varied from 4 years and 7 months to 17 years and 7 months, with a median of 8 years. The mean time since completion of treatment was 13 months, varying from 1 to 36 months.
We observed that all 22 patients vaccination histories included the first dose of measles vaccine, which is compulsory throughout Brazil. 6 The same was not true of the second measles vaccine dose, since two patients had not received it; the rubella vaccine had not been given to four patients. Thus, 4/22 (18.2%) patients analyzed had not followed the vaccination schedule correctly, while the vaccination histories of 18/22 (81.2%) were adequate. to 64% seropositive). These authors consider that leukemia treatment is the greatest contributor to the loss of antibodies, since at diagnosis levels were close to those observed in the normal population. 7 Nilsson et al. assessed 43 children who had completed treatment for ALL, all of whom had been vaccinated against measles and rubella. They found just 60% seropositivity for measles and 72% for rubella; levels below those expected for the healthy population. They suggested that all children be revaccinated at the end of treatment. 8 Brodtman et al. observed 52% positivity for measles and 76% for rubella among 99 children treated for ALL and off therapy for 1 year. 9 In our study we observed that 65% of the children had maintained adequate measles antibodies after completion of treatment, which is very similar to the results reported by the authors cited above. Nevertheless, positivity of 60-65% is well below the 95-99% seroconversion after the basic measles vaccination schedule expected for the healthy general population, 10 and means that more than 25% of our patients were vulnerable to measles.
This reduction in seropositivity rates is probably the result of the loss of protective antibody that had been induced by previous vaccination during leukemia treatment, as described by Feldman et al. 7 In our study this statement is an inference since we are limited by the fact that antibodies against measles and rubella were not assayed OPV, HiB and the triple viral vaccine. 13 As we have observed, the conduct of immunizations with conventional chemotherapy patients is controversial.
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chemotherapy protocols, we recommend measles booster vaccination for all children with ALL after completion of treatment. Each patients serological status should be assessed separately for rubella, with vaccination of unprotected patients.
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